carbazochrome 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	491	69-81-8

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

carbazochrome
adrenochrome monosemicarbazone
adrenostazin
carbazochrom
carbazochrome salicylate

a hemostatic which increases capillary resistance & activates platelet factors, Note: Adona is a multimeaning tradename

Molecular weight: 236.23
Formula: C10H12N4O3
CLOGP: -0.39
LIPINSKI: 0
HAC: 7
HDO: 3
TPSA: 108.02
ALOGS: -1.91
ROTB: 1

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3A,GSK3B,IKBKB,IRAK1,ITK,JAK1,JAK2,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM1,PIM2,PIM3,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2	74
kinase-selectivity-class	ACVR2A,ACVR2B,AXL,BRAF,CAMK2D,CDK16,CDK4,CDK9,CLK2,CLK4,DDR1,DYRK1A,DYRK1B,EIF2AK3,GRK2,GSK3A,GSK3B,HIPK2,IRAK1,JAK2,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K7,MAPK7,MARK4,PDK1,PIM3,PRKAA1,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ULK1	38
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Oesophagitis	68.83	55.34	15	150	15232	42605938

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Oesophagitis	62.01	35.80	15	335	28700	110560249

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B02BX02	BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS VITAMIN K AND OTHER HEMOSTATICS Other systemic hemostatics
MeSH PA	D003029	Coagulants
MeSH PA	D006401	Hematologic Agents
MeSH PA	D006490	Hemostatics

Related Drugs by ATC class:

B02BX Other systemic hemostatics 10 drugs

avatrombopag concizumab eltrombopag emicizumab etamsylate fitusiran fostamatinib lusutrombopag marstacimab-hncq romiplostim

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.86	acidic
pKa2	2.34	Basic
pKa3	1.41	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D01864	KEGG_DRUG
2011	RXNORM
C0006972	UMLSCUI
CHEBI:31349	CHEBI
CHEMBL2051960	ChEMBL_ID
DB09012	DRUGBANK_ID
C073338	MESH_SUPPLEMENTAL_RECORD_UI
2557	PUBCHEM_CID
210	INN_ID
13051-01-9	SECONDARY_CAS_RN
81F061RQS4	UNII
703411008	SNOMEDCT_US
704671001	SNOMEDCT_US
90342008	SNOMEDCT_US
263	INN_ID
002094	NDDF
004780	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
IGATAN F	HUMAN OTC DRUG LABEL	3	72689-0027	CAPSULE	2 mg	ORAL	unapproved drug other	7 sections